

Image

1651



Rev 09/03

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : MICHAEL VALENTINE AGREZ, ET AL.
Application No. : 10/019,816
Filed : March 27, 2002
Confirmation No. : 9944
For : METHOD OF MODULATING INTEGRIN MEDIATED CELLULAR
ACTIVITY AND AGENTS USEFUL FOR SAME
Examiner :
Attorney's Docket : SW-046XX (NOW BLAKE-046XX)

TC Art Unit: 1651

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450 on 11-17-03.

By: Charles L. Gagnebin III
Charles L. Gagnebin III
Registration No. 25,467
Attorney for Applicant(s)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT is in follow-up
to the Supplemental IDS filed October 23, 2003. No new references are
cited herein. References cited but not enclosed in the October 23, 2003
IDS are now being furnished to the U.S. Patent Office.

It is desired to cite for the record in this application the
enclosed references listed on the attached copy of PTO Form #1449. The
paragraph(s) marked below are applicable to this Information Disclosure
Statement.

- ☐ (1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached Information Disclosure Statement is being filed within three months of the filing date of the above identified national application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 of the above identified application. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- ☒ (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- ☐ (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- ☐ (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
- ☐ a statement under 37 CFR § 1.97(e); or
- ☐ the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

- ☐ (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(p).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

- ☐ (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a

Application No.: 10/019,816
Filed: March 27, 2002
TC Art Unit: 1651
Confirmation No.: 9944

counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e) (2)

[] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

Please note that ten references are being forwarded, as stated in the Supplemental IDS filed October 23, 2003. One reference cited, WO 01/00677, is in fact the PCT publication of this application (PCT/AU00/00729) which was cited in an International Preliminary Examination Report of a related PCT application by the same inventors. Therefore, we have stricken reference WO 01/00677 from the cited art list. Also, we are enclosing a copy of the complete Carlioni article, which was previously submitted as a PUBMED ABSTRACT.

Application No.: 10/019,816

Filed: March 27, 2002

TC Art Unit: 1651

Confirmation No.: 9944

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

MICHAEL VALENTINE AGREZ, ET AL.

By: 

Charles L. Gagnebin III

Registration No. 25,467

Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,

GAGNEBIN & LEBOVICI LLP

Ten Post Office Square

Boston, Massachusetts 02109

Telephone: (617) 542-2290


Telecopier: (617) 451-0313

CLG/mc/298188-1

Enclosure

Date: November 17, 2003


Page 1 of 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. SW-046XX (now BLAKE-046XX)		APPLICATION NO. 10/019,816	
				APPLICANT: Michael Valentine Agrez, et al.			
				FILING DATE March 27, 2002		TC ART UNIT 1651	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	PUBLICATION/ ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE
		US					
		US					
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS <i>(including Author, Title, Date, Pertinent Pages, etc.)</i>							
	Boulton, T.G., et al., "Mitogen-activated protein kinase 1," (EC 2.7.1) (1991) (Swiss Prot Acc No. P27703) .						
	** Breuss, J.M., et al., "Restricted distribution of integrin $\beta 6$ mRNA in primate epithelial tissues," J Histochem Cytochem (1993), 41: 1521-1527.						
	** Carloni, V., et al., "The integrin $\alpha 6 \beta 1$, is necessary for the matrix-dependent activation of FAK and MAP Kinase and the migration of human hepatocarcinoma cells," Hepatology 2001, Jul; 34(1): 42-9.						
	** Eliceiri, B.P., et al., "The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development," J Clin Invest (1999), 103(9): 1227-30.						
	** Eliceiri, B.P., et al., "Integrin $\alpha v \beta 3$ requirement for sustained mitogen activated protein kinase activity during angiogenesis," J Cell Biol (1998), 140(5): 1255-63.						
	** Friedlander, M., et al., "Definition of two angiogenic pathways by distinct αv integrins," Science (1995), 270(5241): 1500-2.						
	Gonzalez, F.A., "H Sapiens 40kDa protein kinase related to rat ERK2," (1992) (GenPept Acc No. CAA77753).						
	** Gupta, K., et al., "VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling," Exp Cell Res (1999), 247(2): 495-504.						
	Ishii, T., et al., "Integrin-linked Kinase Controls Neurite Outgrowth in N1E-115 Neuroblastoma Cells," J. Biol. Chem. (2001), 276(46): 42994-43003.						
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

**** REFERENCES ENCLOSED** (all references were previously cited in IDS filed October 23, 2003; unstarred items were sent to PTO on 10/23/2003)

Date: November 17, 2003

Page 2 of 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 05/03)		ATTY. DOCKET NO. SW-046XX (now BLAKE-046XX)	APPLICATION NO. 10/019,816			
 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT: Michael Valentine Agrez, et al.				
		FILING DATE March 27, 2002	TC ART UNIT 1651			
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	PUBLICATION/ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE
	US					
	US					
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)						
	** Pagès, G., et al., "Signaling angiogenesis via p42/p44 MAP kinase cascade," Ann NY Acad Sci (2000), 902: 187-200.					
	** Redlitz, A., et al., "Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells." J Vasc Res (1999), 36(1): 28-34.					
	Sugiura, N., et al., "Mus musculus DNA for ERK2," exon 7 (1997) (GenPept Acc No. BAA22620).					
	** Tanaka, K., et al., "Roles of extracellular signal-regulated kinase 1 / 2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis," Jpn J Cancer Res (1999), 90(6): 647-54.					
	** Yu, Y., et al., "MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor," J Cell Physiol (1999), 178(2): 235-46.					
EXAMINER				DATE CONSIDERED		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

CLG/mc/298202-1

** REFERENCES ENCLOSED (all references were previously cited in IDS filed October 23, 2003; unstarred items were sent to PTO on 10/23/2003)